Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company headquartered in Salt Lake City, Utah, with news flow centered on silicon nitride–based medical technologies, implant systems, and infection‑prevention platforms. This news page aggregates company press releases and third‑party coverage so readers can follow developments in its silicon nitride biomaterials, polymer composites, and antipathogenic fabric technologies.
Recent SINTX news highlights regulatory milestones and product launches, including U.S. FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System and the launch of OsseoSculpt, a biologic designed to complement the SINAPTIC wedge portfolio. Updates also cover the company’s focused commercialization plan around infection‑resistant silicon nitride devices and polymer composites, as well as early product revenue from OsseoSculpt.
Investors and industry observers will find coverage of strategic agreements, such as the supply agreement with EVONIK to manufacture SINTX’s proprietary SiN/PEEK compound for AI‑assisted, 3D‑printed, patient‑specific implants. News items also track SINTX’s intellectual‑property progress, including Notices of Allowance from the United States Patent and Trademark Office for composition and method patents covering antipathogenic fibrous materials and fabric technologies.
In addition, SINTX issues releases on capital markets activity and corporate events, including warrant exercises, at‑the‑market offering arrangements, and participation in investor conferences hosted by firms such as H.C. Wainwright and Sidoti & Company. These updates provide context on the company’s financing strategy and investor outreach.
By monitoring this page, readers can review SINTX news related to medical device clearances, biologic product introductions, infection‑prevention patents, financing transactions, and investor presentations, all in one place.
SINTX Technologies has been awarded a $308,301 Phase 1 grant by the NIH to develop a 3-D printed silicon nitride – polyetheretherketone (SN-PEEK) spinal implant. This research focuses on enhancing the antibacterial and osseointegrative properties of silicon nitride. The project aims to capitalize on existing PEEK implant technology while integrating novel characteristics. Collaborating with notable universities, SINTX is positioned to advance spinal implant technology and plans to pursue a Phase 2 grant upon completion of this project.
SINTX Technologies held its annual meeting of stockholders on September 15, 2021, which was adjourned due to a lack of quorum. A majority of the outstanding shares entitled to vote was not present. The meeting is now rescheduled for October 13, 2021, at 10:30 a.m. MT. Stockholders of record as of July 26, 2021, are urged to vote by October 12, 2021. Approximately 44% of shares represented by proxies had been submitted. The company plans to further solicit votes and may incur additional costs if a quorum is not achieved at the adjourned meeting.
SINTX Technologies has established a new subsidiary, SINTX Armor, based in Salt Lake City, Utah, with plans to operate by the end of 2021. The company signed a decade-long lease for a facility that will focus on developing and manufacturing advanced ceramic armor, including boron carbide torso plates. This move aims to capture a share of the U.S. Department of Defense and law enforcement markets. SINTX has already shipped its first prototype order and aims to enhance innovation and operational efficiency in armor production.
SINTX Technologies announced the hiring of Joseph Palomo as Vice President of Business Development for its antipathogenic segment. The company is focusing on expanding its capabilities in manufacturing antipathogenic silicon nitride powders, with the AP2 and AP4 grades showing enhanced efficacy against pathogens, including SARS-CoV-2 variants. SINTX is pursuing U.S. EPA registration and has collaborations in place with European firms and universities. Additionally, ongoing research confirms silicon nitride's effectiveness in neutralizing various viruses, positioning SINTX for growth in protective textile applications.
SINTX Technologies (NASDAQ: SINT) has announced a reassessment of its exclusive Patent License Agreement with O2TODAY after O2TODAY revealed regulatory hurdles delaying the launch of its SiNPRO filters and masks. O2TODAY is refunding pre-orders due to these issues. SINTX is now considering a return to initial joint development efforts with O2TODAY as it seeks alternative routes to market its antipathogenic facemask technology. This is part of SINTX's broader strategy to develop various medical applications using silicon nitride.
SINTX Technologies announced the first shipment of its new FleX SN-PEEK product, launched on July 20, 2021, designed for orthopedic implants. This innovative composite material combines the bioactivity of silicon nitride with the established properties of Zeniva PEEK, enhancing bone healing and infection resistance. The product aims to improve surgical outcomes across various applications, including spine surgery and joint replacements. SINTX continues to expand its customer base in the biomedical market, leveraging its expertise in manufacturing silicon nitride ceramics.
SINTX Technologies (NASDAQ: SINT) announced the acquisition of equipment and processes from B4C, LLC for manufacturing ballistic armor plates. Additionally, SINTX signed a technology license with Precision Ceramics USA Inc. to create a ceramic composite for defense applications. The new subsidiary, SINTX Armor, aims to produce high-strength Boron Carbide and a cost-effective Boron Carbide-Silicon Carbide composite. This move diversifies SINTX’s product offerings into military and law enforcement markets, addressing growing demand for advanced armor solutions.
SINTX Technologies (NASDAQ: SINT) announced a significant milestone by shipping its first batch of FleX SN-AP antipathogenic silicon nitride powder to O2TODAY for use in face masks and filters. This marks the next phase of their collaboration established during the COVID-19 pandemic. O2TODAY plans to begin limited pre-orders for these products on July 6, 2021. The agreement includes a two-year technology license, allowing exclusive use of SINTX's technology in these applications, promising potential royalties from product sales.
Oxford Performance Materials (OPM) and SINTX Technologies (NASDAQ: SINT) announced a collaboration to develop a new poly-ether-ketone-ketone (PEKK) silicon nitride composite using OPM’s patented casting technology.
This partnership aims to enhance medical implants' biological response and reduce infection rates, potentially leading to faster recovery and improved patient outcomes.
Both companies emphasize their shared focus on nanotechnology and surface technologies, suggesting that this collaboration could yield innovative products in the biomedical field.
SINTX Technologies, Inc. (NASDAQ: SINT) has been included in the Russell Microcap Index, effective June 4, 2021. This inclusion recognizes SINTX's financial progress and its focus on silicon nitride applications in biomedical and commercial markets. The Russell Microcap Index serves as a benchmark for institutional investors to evaluate micro-cap stocks with market caps between $50 and $300 million. CEO Dr. Sonny Bal emphasized that this achievement reflects SINTX's innovation in developing products like wound care, spinal and dental implants, and consumer facemasks.
FAQ
What is the current stock price of Sintx Technologies (SINT)?
What is the market cap of Sintx Technologies (SINT)?
